CAS: 1329499-27-5

Ravuconazole-d4 is a potent inhibitor of human vitamin K epoxide reductase, an enzyme that is essential for the activation of vitamin K-dependent proteins involved in blood coagulation and bone metabolism. It has been shown to induce apoptosis in tumor cells through the inhibition of protein kinase B (AKT) and mammalian target of rapamycin (mTOR) signaling pathways. Ravuconazole-d4 also exhibits anticancer activity by inhibiting cell cycle progression and inducing apoptosis in various cancer cell lines, including Chinese hamster ovary cells. In addition, this compound has been detected in urine samples from patients receiving ravuconazole therapy, indicating its potential as a biomarker for monitoring drug efficacy or toxicity. Overall, Ravuconazole-d4 holds great promise as a potent inhibitor of tumor growth and a valuable tool for cancer research.

Applications Ergosterol biosynthesis inhibitor. Antifungal. References Fung-Tomc., J.C., et al.: Antimicrob. Agents Chemother., 42, 313 (1988), Tsuruoka, A., et al.: Chem. Pharm. Bull., 46, 623 (1998), Gupta, A.K., et al.: J. Eur. Acad. Dermatol. Venereol., 19, 437 (2005),